07:00 , Oct 17, 2011 |  BioCentury  |  Finance

Banker tracks

April Young joined Hercules Technology Growth Capital Inc. (NASDAQ: HTGC) as managing director. She will head a new office in McLean, Va. Young was SVP and managing director of the Mid-Atlantic technology and life sciences...
07:00 , Apr 12, 2004 |  BioCentury  |  Strategy

Indevus' pipeline

Indevus' pipeline Product Indication Status Licensor Sanctura trospium Overactive bladder PDUFA date May 28 Madaus Pagoclone General anxiety and panic disorders Start additional Ph III 2H04 Aventis PRO 2000 HIV and STD prevention Moving into...
08:00 , Dec 23, 2002 |  BC Week In Review  |  Company News

Atlantic Technology, Manhattan deal

ATLC will merge with Manhattan, which develops therapeutics for obesity. Upon completion of the merger, ATLC shareholders will own about 20% and Manhattan will own about 80% of the combined company. Manhattan shareholders will become...
08:00 , Dec 17, 2002 |  BC Extra  |  Company News

ATLC to merge with Manhattan Pharma

Atlantic Technology Ventures (ATLC) will merge with Manhattan Pharmaceuticals (New York, N.Y.), which develops therapeutics for obesity. Upon completion of the merger, ATLC will own about 20% and Manhattan will own about 80% of the...
08:00 , Dec 9, 2002 |  BC Week In Review  |  Clinical News

IP 751: Phase II

In a placebo-controlled Phase II study of 21 patients with chronic pain resulting from spinal or peripheral nerve injuries, IP 751 gave a significant reduction in neuropathic pain, as measured by visual analog scores (p<0.05)....
08:00 , Dec 9, 2002 |  BioCentury  |  Finance

Ebb & Flow

The preferred currency for biotech M&A has been stock rather than cash, because most CEOs want to keep the latter to fund R&D. Thus, it's notable that Triangle (VIRS) is the third Warburg Pincus portfolio...
08:00 , Dec 3, 2002 |  BC Extra  |  Clinical News

Indevus Phase II pain data

IDEV said its IP 751 (formerly CT-3 ) synthetic cannabinoid gave a significant reduction in neuropathic pain in a placebo-controlled Phase II study of 21 patients with chronic pain resulting from spinal or peripheral nerve...
07:00 , Jul 15, 2002 |  BC Week In Review  |  Company News

Atlantic Technology, University of Innsbruck deal

ATLC licensed from the university rights to ATV-02, a broad spectrum antimicrobial agent in Phase II testing for viral and bacterial conjunctivitis as well as acute and chronic sinusitis. ATLC said ATV-02 is a natural...
07:00 , Jul 8, 2002 |  BC Week In Review  |  Company News

Atlantic Technology, Indevus deal

IDEV received an exclusive worldwide license from ATLC to CT-3 anti-inflammatory and analgesic compound. CT-3 is a synthetic derivative of tetrahydrocannabinol (THC) that the companies said appears to inhibit inflammatory cytokines such as interleukin-1 beta...
07:00 , Jul 1, 2002 |  BC Extra  |  Company News

Indevus licenses ATLC compound

IDEV received an exclusive worldwide license from Atlantic Technology Ventures (ATLC) to CT-3 anti-inflammatory and analgesic compound. CT-3 is a synthetic derivative of tetrahydrocannabinol (THC) that the companies said appears to inhibit inflammatory cytokines such...